Cutting Edge Information's Industry Experts Ready to Comment on Election's Impact on Pharmaceutical Business

RESEARCH TRIANGLE PARK, NC--(Marketwire - November 6, 2008) - Cutting Edge Information has made its research team available to writers or editors seeking analysis of what changes the pharmaceutical industry could see now that the 2008 election has concluded. While political changes can present new challenges, Cutting Edge Information expects the clarity of the post-election period to help the industry make better-informed decisions about how to return to growth.

"The pharmaceutical and biotechnology industries have been changing rapidly over the last five years," said Jason Richardson, president of Cutting Edge Information. "The competitive and regulatory environments have shifted, and in many ways this is a more challenging world than we've seen in the last fifteen years. However, I believe there is a great deal that pharma and biotech companies can do to prosper and grow going forward. With the fog of the election season receding, it's time to get down to business."

Elio Evangelista, research manager, noted the especially rapid changes taking place in how pharmaceutical companies communicate with physicians. "While the general sales forces are being cut, we see more specialized forces working in hyperdrive to get scientific information out," said Evangelista. "Scientific and medical affairs groups are growing by leaps and bounds. We think this heightened emphasis on delivering high-quality clinical information will help address a perception in healthcare that pharma teams are visiting too often with the same information."

"Both pharmaceutical and biotechnology companies have massive pipelines of potential drugs," said Eric Bolesh, research manager. "But the cost of successfully bringing a drug to market has been a drag on this wave of innovation. Companies are facing the end of patent protection on a whole generation of blockbusters and working to make the promise of personalized medicine a reality. With smart business development, clinical development and portfolio management, all of these companies can build the next generation of successful products and really push the science forward."

"Political change may bring new competitive or regulatory developments," said Richardson. "Next year we're looking at four or five percent global growth, with only one to two percent in the U.S. But this is a fast-moving, adaptable industry and we expect to see positive developments on both the scientific and business fronts in the next few years."

Contact Information: For media inquiries, please contact: Stephanie Swanson 919-433-0212